J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 29.87 CNY -4.57% Market Closed
Market Cap: 24.1B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Jafron Biomedical Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jafron Biomedical Co Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
J
Jafron Biomedical Co Ltd
SZSE:300529
Additional Paid In Capital
ÂĄ711.8m
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Additional Paid In Capital
ÂĄ724m
CAGR 3-Years
66%
CAGR 5-Years
46%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Additional Paid In Capital
ÂĄ2B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
40%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Additional Paid In Capital
ÂĄ6.9B
CAGR 3-Years
-5%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Additional Paid In Capital
ÂĄ3.5B
CAGR 3-Years
53%
CAGR 5-Years
123%
CAGR 10-Years
17%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Additional Paid In Capital
ÂĄ13.9B
CAGR 3-Years
64%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
24.1B CNY
Industry
Health Care

Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.

Intrinsic Value
47.02 CNY
Undervaluation 36%
Intrinsic Value
Price
J

See Also

What is Jafron Biomedical Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
711.8m CNY

Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Additional Paid In Capital amounts to 711.8m CNY.

What is Jafron Biomedical Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
4%

Over the last year, the Additional Paid In Capital growth was 3%. The average annual Additional Paid In Capital growth rates for Jafron Biomedical Co Ltd have been 10% over the past three years , 4% over the past five years .

Back to Top